12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA

Article Information

DOI 
http://dx.doi.org/10.1177/155989771209010
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2012 MD Conference Express®

Author Information

  1. Maria Vinall
  1. Edward Keystone, MD
    1. University of Toronto, Toronto, Ontario, Canada
View Full Text

Article usage

AbstractFullPDF
Apr 20151500
Jun 2015300
Jul 2015111
Aug 2015300
Sep 2015200
Oct 2015132
Nov 2015100
Total2643

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Rheumatoid Arthritis Clinical Trials